Safety Reporting

Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.

 

4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.

The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.

The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.

4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.

4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).

Clinical Research News

Une piqûre contre l'arthrose ? Des scientifiques font état de la réparation d'articulations chez l'animal en quelques semaines
Pfizer va tester un nouveau vaccin pneumococcique pour les enfants nécessitant une vaccination de rattrapage
Le traitement de la tuberculose est un long marathon. Un nouvel essai testera s'il peut être réduit à 17 semaines
Après le diagnostic de diabète de type 1, la course contre la montre commence. Un nouvel essai tentera de préserver l'insuline naturelle
À quel point le "mauvais" cholestérol doit-il être bas ? Un essai teste une nouvelle cible pour les patients à très haut risque
Le DYNE-251 testé dans un essai de phase 3 chez des patients atteints de dystrophie musculaire de Duchenne
Le GLP-1 oral testé chez des personnes atteintes de diabète de type 2 jeûnant pendant le Ramadan

Prochains essais cliniques

Clinical Research Jobs

More jobs

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner